ArticleCancer microenvironment : official journal of the International Cancer Microenvironment Society2010
The tumor microenvironment in colorectal carcinogenesis.
Article in Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 132 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
132 citing papers in PubMed.
- Trial
- Trial
- Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.Cancer medicine · 2018Trial
- Neural cues differentially modulate colorectal cancer cell behavior depending on patients' genomic background.iScience · 2026Article
- Revisiting Colon Cancer Progression: A Containment-Based Conceptual Framework.Life (Basel, Switzerland) · 2026Article
- Tumour immune cell infiltration and response to FOLFOX or FOLFIRI chemotherapy in colorectal cancer.The pharmacogenomics journal · 2026Article
- Exosomal CeRNAs from the tumor microenvironment: hidden drivers of colorectal cancer progression.Journal of molecular histology · 2026Review
- Enhancing NK Cell Activity in Colorectal Cancer with an Fc-Optimized Antibody Targeting CD276 (B7-H3).ImmunoTargets and therapy · 2026Article
- P62 in colorectal cancer: from inflammation suppression to cancer promotion.Frontiers in immunology · 2026Review
- Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases.Oncology research · 2026Review
- CD300e is a driver of the immunosuppressive tumor microenvironment and colorectal cancer progression via macrophage reprogramming.Journal for immunotherapy of cancer · 2025Article
- Article
- Clinicopathological characterization of enteric glia in colorectal cancer: Insights from a population-based cohort.Journal of neuropathology and experimental neurology · 2025Article
- The Role of Tumor-Infiltrating B Lymphocytes in Colorectal Cancer Patients: A Systematic Review of Immune Landscape Evolution.Cancers · 2025Review
- Advanced diffusion-weighted imaging biomarkers for non-invasive assessment of tumor microenvironment in rectal cancer: restricted spectrum imaging.Abdominal radiology (New York) · 2025Article
- Proteomic profiling identifies a stromal TGF-β1/podoplanin axis as a driver of colorectal cancer progression.Journal of experimental & clinical cancer research : CR · 2025Article
- Gut microbiota influences colorectal cancer through immune cell interactions: a Mendelian randomization study.Discover oncology · 2025Article
- 5-Bromouracil-gracillin (5BrU-G) complex: an APOBEC3-activated therapeutic strategy exploiting cancer-specific enzymatic activity for selective cytotoxicity.Medical oncology (Northwood, London, England) · 2025Article
- Article
- Colorectal cancer stem cells crosstalk in tumor immune microenvironment and targeted therapeutic strategies.Frontiers in immunology · 2025Review
72 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Colorectal cancer is the second leading cause of cancer-related mortality in the United States. Therapeutic developments in the past decade have extended life expectancy in patients with metastatic disease. However, metastatic colorectal cancers remain incurable. Numerous agents that were demonstrated to have significant antitumor activity in experimental models translated into disappointing results in extending patient survival. This has resulted in more attention being focused on the contribution of tumor microenvironment to the progression of a number of solid tumors including colorectal cancer. A more complete understanding of interactions between tumor epithelial cells and their stromal elements will enhance therapeutic options and improve clinical outcome. Here we will review the role of various stromal components in colorectal carcinogenesis and discuss the potential of targeting these components for the development of future therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.